SCHEMBL1457321

SCHEMBL1457321

CCC[C@H]1CC[C@H](c2ccc(N=C=S)cc2)CC1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.52
▸ MAPK1 P28482 1/20 0.52
▸ KMT2A Q03164 1/20 0.52
▸ CYP2C9 P11712 3/20 0.51
▸ ALDH1A1 P00352 1/20 0.49
▸ LMNA P02545 1/20 0.49
▸ MAPT P10636 1/20 0.49
▸ ESR2 Q92731 5/20 0.41
▸ P2RY6 Q15077 1/20 0.40
▸ ESR1 P03372 3/20 0.36
▸ CYP3A4 P08684 2/20 0.36
▸ MIF P14174 1/20 0.35
▸ NOS3 P29474 2/20 0.34
▸ NOS1 P29475 2/20 0.34
▸ NOS2 P35228 2/20 0.34
▸ SPHK1 Q9NYA1 1/20 0.33
▸ CHEK2 O96017 1/20 0.33
▸ DRD2 P14416 1/20 0.33
▸ CYP2D6 P10635 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3791147 1.00 MEN1 (0.52) MEN1MAPK1KMT2ACYP2C9ALDH1A1
SCHEMBL10348069 0.98 MEN1 (0.51) MEN1MAPK1KMT2ACYP2C9ALDH1A1
SCHEMBL10348049 0.96 MEN1 (0.49) MEN1MAPK1KMT2ACYP2C9ALDH1A1
SCHEMBL10417322 0.96 MEN1 (0.49) MEN1MAPK1KMT2ACYP2C9ALDH1A1
SCHEMBL10532002 0.96 MEN1 (0.49) MEN1MAPK1KMT2ACYP2C9ALDH1A1
SCHEMBL10531997 0.96 MEN1 (0.49) MEN1MAPK1KMT2ACYP2C9ALDH1A1
SCHEMBL10347974 0.96 MEN1 (0.49) MEN1MAPK1KMT2ACYP2C9ALDH1A1
SCHEMBL10348559 0.96 MEN1 (0.49) MEN1MAPK1KMT2ACYP2C9ALDH1A1
SCHEMBL10347893 0.93 P2RY6 (0.53) MEN1MAPK1KMT2ACYP2C9ALDH1A1
SCHEMBL10347892 0.93 P2RY6 (0.53) MEN1MAPK1KMT2ACYP2C9ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010064239-A1 APPARATUS AND METHODS FOR DIAGNOSING RENAL DISORDERS TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) 2010-06-10 — — WO claimed
WO-2010065329-A2 NANOPARTICLES FOR CANCER TREATMENT THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2010-06-10 — — WO claimed
US-20060241178-A1 Compositions and methods for treating lung cancer IMMUNEGUARD LLC (US) 2006-10-26 — — US claimed
US-20010044012-A1 Transparent substrate between a hydrophilic ink receiving layer and a colored hydrophobic luminescent layer; creating photographic quality prints XEROX CORPORATION 2001-11-22 — — US claimed
US-6319591-B1 Ink jet recording substrates XEROX CORPORATION 2001-11-20 — — US claimed
EP-0743574-B1 Migration imaging members XEROX CORP (US) 2000-12-27 — — EP claimed
EP-0743573-B1 Method for obtaining image contrast migration imaging members XEROX CORP (US) 2000-09-06 — — EP claimed
US-5958119-A Hot melt ink compositions XEROX CORPORATION (US) 1999-09-28 — — US claimed
US-5846637-A Coated xerographic photographic paper XEROX CORPORATION (US) 1998-12-08 — — US claimed
EP-0743573-A2 Method for obtaining image contrast migration imaging members XEROX CORPORATION (US) 1996-11-20 — — EP claimed
EP-0743574-A2 Migration imaging members XEROX CORPORATION (US) 1996-11-20 — — EP claimed
US-5563014-A SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT XEROX CORPORATION (US) 1996-10-08 — — US claimed
US-5514505-A SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE XEROX CORPORATION (US) 1996-05-07 — — US claimed
EP-0126883-B1 LIQUID CRYSTALLINE CYCLOHEXYLBENZENE DERIVATIVES, THEIR PREPARATION AND THE LIQUID CRYSTAL COMPOSITIONS CONTAINING THEM Wojskowa Akademia Techniczna im. Jaroslawa Dabrowskiego (PL) 1987-03-11 — — EP claimed
EP-0126883-A1 Liquid crystalline cyclohexylbenzene derivatives, their preparation and the liquid crystal compositions containing them Wojskowa Akademia Techniczna im. Jaroslawa Dabrowskiego (PL) 1984-12-05 — — EP claimed
US-20240190866-A1 POLYHYDROXYLATED INDOLIZIDINE AND PYRROLIZIDINE DERIVATIVES AND USES THEREOF ACADEMIA SINICA (TW) 2024-06-13 — — US disclosed
EP-4308108-A1 POLYHYDROXYLATED INDOLIZIDINE AND PYRROLIZIDINE DERIVATIVES AND USES THEREOF Academia Sinica (TW) 2024-01-24 — — EP disclosed
WO-1986003769-A1 LIQUID CRYSTALLINE PHASE MERCK Patent Gesellschaft mit beschränkter Haftung (DE) 1986-07-03 — — WO disclosed
EP-0170082-A2 Liquid crystalline isothiocyanates with a dioxane ring and liquid crystalline admixtures containing the same Wojskowa Akademia Techniczna im. Jaroslawa Dabrowskiego (PL) 1986-02-05 — — EP disclosed
EP-0126883-A1 Liquid crystalline cyclohexylbenzene derivatives, their preparation and the liquid crystal compositions containing them Wojskowa Akademia Techniczna im. Jaroslawa Dabrowskiego (PL) 1984-12-05 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240190866-A1 POLYHYDROXYLATED INDOLIZIDINE AND PYRROLIZIDINE DERIVATIVES AND USES THEREOF PHKB, BET1, IDO1 MEN1 3949/4885MAPK1 4689/4885KMT2A 2447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback